Genmab A/SGMABNASDAQ
Loading
Operating Income Growth Recovery in ProgressRecovering
Percentile Rank72
3Y CAGR+92.1%
5Y CAGR+133.9%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
+92.1%/yr
vs -37.8%/yr prior
5Y CAGR
+133.9%/yr
Recent deceleration
Acceleration
+129.9pp
Accelerating
Percentile
P72
Within normal range
vs 5Y Ago
69.9x
Strong expansion
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 236.40% |
| Q3 2025 | -79.88% |
| Q2 2025 | 1113.47% |
| Q1 2025 | -91.30% |
| Q4 2024 | 2.76% |
| Q3 2024 | 790.68% |
| Q2 2024 | 103.45% |
| Q1 2024 | -93.05% |
| Q4 2023 | -0.89% |
| Q3 2023 | 14.78% |
| Q2 2023 | 252.04% |
| Q1 2023 | -83.81% |
| Q4 2022 | 33.35% |
| Q3 2022 | 54.85% |
| Q2 2022 | 142.61% |
| Q1 2022 | -36.46% |
| Q4 2021 | -9.10% |
| Q3 2021 | 13.09% |
| Q2 2021 | 47.93% |
| Q1 2021 | -40.02% |
| Q4 2020 | 3.38% |
| Q3 2020 | -80.92% |
| Q2 2020 | 6233.80% |
| Q1 2020 | -96.74% |
| Q4 2019 | 519.95% |
| Q3 2019 | 155.89% |
| Q2 2019 | 627.57% |
| Q1 2019 | -103.61% |
| Q4 2018 | 260.20% |
| Q3 2018 | 48.23% |
| Q2 2018 | -58.33% |
| Q1 2018 | -53.93% |
| Q4 2017 | 1106.49% |
| Q3 2017 | -89.13% |
| Q2 2017 | 1064.35% |
| Q1 2017 | -93.49% |
| Q4 2016 | 278.88% |
| Q3 2016 | 31.78% |
| Q2 2016 | 767.75% |
| Q1 2016 | -95.65% |